Compare Ascendis Pharma A/S (ASND) vs Gold Fields Limited (GFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Gold Fields Limited — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Gold Fields Limited trades at $33.98 (market cap $30.43B). The key difference: Gold Fields Limited is the larger of the two by market cap, and Gold Fields Limited pays a 6.79% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GFI | |
|---|---|---|
Market Cap | $17.74B | $30.43B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $61.52 |
52-Week Low | $163.32 | $23.95 |
Enterprise Value | $18.11B | $31.87B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Gold Fields (GFI) trades at $34.14, up 0.29% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 40.76% net income margin and 52.33% ROE, supported by revenue growth from $5.2B in 2024 to a projected $8.8B in 2025. Recent news highlights operational challenges amid gold price volatility, with Q1 2025 production up 15% but costs rising 13% due to inflation (Seeking Alpha, 2026-06-29).
The outlook is mixed: analyst consensus is a Buy with a $53.13 price target, implying 56% upside, but technical weakness and earnings misses in Q2 and Q4 2025 pose near-term risks. Long-term value hinges on cost control and gold price stability, with debt-to-asset ratio improvements from 25.01% in 2024 to 18.27% in 2025 signaling stronger balance sheet health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
